Cramer's 'Mad Money' Recap: Once Hated, Now Loved

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK ( TheStreet) -- Investors are like most TV watchers, always changing channels, Jim Cramer told his "Mad Money" TV show viewers Thursday. He opined about a multitude of stocks that were once hated but are now loved as investors have once again changed their minds.

No stock illustrates this move better than Facebook ( FB), a stock Cramer owns for his charitable trust, Action Alerts PLUS . Cramer said that after the worst IPO in history, Facebook has emerged as the king of mobile and social advertisers. He's still a buyer of Facebook, along with Google ( GOOG).

Other sectors that are getting a second look include travel, thanks to TripAdvisor ( TRIP), and the airlines, with US Airways ( LCC) leading the charge.

Biotech remains a hot sector, with Cramer recommending Celgene ( CELG) and Regeneron ( REGN) as just two of many faves. He was also bullish on housing, despite disappointments from D.R. Horton ( DHI). He said that news won't affect ancillary housing stocks such as Home Depot ( HD) and Restoration Hardware ( RH).

Other Cramer faves include the autos, banks and oil and gas stocks, along with some technology and semiconductor names. Cramer even had kind words for Starbucks ( SBUX) and Dunkin' Brands ( DNKN).

Executive Decision: Tarek Sherif

In the "Executive Decision" segment, Cramer spoke with Tarek Sherif, founder, chairman and CEO of Medidata Solutions ( MDSO), the cloud computing provider to the health care industry that's seen it shares rise by 30% since Cramer last spoke with Sherif just six weeks ago.

Sherif said the Food and Drug Administration is mandating that the industry change the way it performs clinical trials, and Medidata is the prime beneficiary of that mandate. He said by using modern cloud technology, Medidata is driving value by improving the quality of trials with less risk and helping to bring better drugs to market faster.

Sherif said clinical trials are still largely in the early stages of using technology, but those that have embraced the technology are getting through their trials faster. He said Medidata has a terrific business model where 80% to 90% of its revenue stems from repeat customers.

If you liked this article you might like

7 Essential Rules for Investing in Tech Stocks

LA Times Tops 100,000 in Digital Subscriptions

Kraft Heinz's New CFO Is Just 29

These Powerful Corporate Executives Could Make a Run at the Presidency in 2020

PayPal CEO Reveals How Silicon Valley Could Repair Its Broken Culture